A Phase Ib Trial of Fulvestrant, Palbociclib (CDK4/6 Inhibitor) and Erdafitinib (JNJ- 42756493,Pan-FGFR Tyrosine Kinase Inhibitor) in ER+/HER2-/FGFR-Amplified Metastatic Breast Cancer (MBC)
Phase of Trial: Phase I
Latest Information Update: 12 Jul 2019
Price : $35 *
At a glance
- Drugs Erdafitinib (Primary) ; Fulvestrant (Primary) ; Palbociclib (Primary)
- Indications Advanced breast cancer
- Focus Adverse reactions
- 21 Jan 2019 Status changed from suspended to recruiting.
- 10 Jan 2019 Status changed from recruiting to suspended.
- 31 Aug 2018 Biomarkers information updated